Gentiva(R) Health Services Sells Selected Pediatric Home Health Car...( expects assumes trends and similar...),Health
Navigation Links
Gentiva(R) Health Services Sells Selected Pediatric Home Health Care Branches
Date:2/17/2009
"expects," "assumes," "trends" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon the Company's current plans, expectations and projections about future events. However, such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the following: economic and business conditions, including the ability to access capital markets; demographic changes; changes in, or failure to comply with, existing governmental regulations; legislative proposals for healthcare reform; changes in Medicare and Medicaid reimbursement levels; effects of competition in the markets in which the Company operates; liability and other claims asserted against the Company; ability to attract and retain qualified personnel; availability and terms of capital; loss of significant contracts or reduction in revenues associated with major payer sources; ability of customers to pay for services; business disruption due to natural disasters or terrorist acts; ability to successfully integrate the operations of acquisitions the Company may make and achieve expected synergies and operational efficiencies within expected time-frames; effect on liquidity of the Company's debt service requirements; a material shift in utilization within capitated agreements; and changes in estimates and judgments associated with critical accounting policies and estimates. For a detailed discussion of certain of these and other factors that could cause actual results to differ from those contained in this news release, please refer to the Company's various filings with the Securities and Exchange Commission (SEC), including the "R
'/>"/>
| SOURCE Gentiva Health Services Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Gentiva(R) Health Services Schedules Fourth Quarter and Fiscal 2008 Earnings Call and Web Cast for Wednesday, February 18, 2009
2. Gentiva(R) Health Services to Present January 13 at J.P. Morgan Healthcare Conference in San Francisco
3. Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens
4. Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 31, 2008
5. Gentiva(R) Health Services to Present June 24 at Jefferies 2nd Annual Healthcare Conference in New York
6. Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider
7. Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York
8. Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook
9. Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008
10. Gentiva(R) Health Services to Present April 16 at the SunTrust Robinson Humphrey 37th Annual Institutional Unconference in Atlanta
11. Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami
Post Your Comments:
(Date:3/17/2010)... to Make it Worse , ... , , ... ... ... , March 17 The health care crisis hundreds of thousands of Idahoans face every day may have just gone from bad to ...
(Date:3/17/2010)... 6 million Americans don,t know they have type 2, experts ... percent of Americans have prediabetes and are at high risk ... , "Look around you. We are surrounded by [diabetes] risk," ... the American Diabetes Association, said in a news release. She ... now. One of the first steps is to find out ...
(Date:3/17/2010)... increase, so do the number of heart attack ... (HealthDay News) -- The availability of public automated ... a heart attack with little neurological consequences, suggests ... are available nationwide, a study found that about ... arrest from an irregular heart rhythm survived with ...
(Date:3/17/2010)... and Renewal of the Child Nutrition Act , ... , , ... ... WASHINGTON ... ...
(Date:3/17/2010)... Researchers from The University of Texas M. D. ... study of women with advanced or recurrent endometrial ... produced a response rate in fifty percent of ... M. D. Anderson,s Department of Gynecologic Oncology, presented ... Society of Gynecologic Oncologists, 41st Annual Meeting on ...
Breaking Medicine News(10 mins):Health News:Gov. Signs Law Putting Politics Before Patients 2Health News:Gov. Signs Law Putting Politics Before Patients 3Health News:Online, Phone Tests Assess Diabetes Risk 2Health News:Widespread Public Defibrillators May Save Lives 2Health News:Widespread Public Defibrillators May Save Lives 3Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 2Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 3Health News:Researchers find new chemotherapy combination shows promise in endometrial cancer 2[0] Gov. Signs Law Putting Politics Before Patients[1] Online, Phone Tests Assess Diabetes Risk[0] Widespread Public Defibrillators May Save Lives[0] More Money, Increased Participation and Higher Nutritional Standards for School Meals[0] Researchers find new chemotherapy combination shows promise in endometrial cancer
... new study, researchers from Cancer Research Insitiute, UK suggests that ... to those on placebo.// They report on a large scale ... 6050 women aged 36 to 65 years, from the UK, ... for five years. All the women were considered as being ...
... rescues patients suffering potentially fatal liver complications from cancer ... a stem cell transplant// such as a bone marrow ... five to 50 per cent of such patients to ... which damages circulation in the liver. ,In ...
... Diseases Centre (CDC) at Atlanta identify a rare strain of ... this year. The new cholera pathogen, transmitted through sea food, ... the world. // ,The reason behind its spread through ... discovery. “We received calls from the US asking us to ...
... Texas observed that Viagra could be used to treat ... based on a small experiment in healthy young men,// ... people with chronic heart and lung disease. ... treating people with pulmonary hypertension (caused by conditions such ...
... high-tech abortion drug being freely sold over the counter ... do-it-yourself-abortions,// experts fear. Already, the sale is brisk as ... as the pharmaceutical concerns treat the city gynaecologists to ... approach to medical abortion”, the tribe is clearly a ...
... the Mayo Clinic are observing new techniques to exercise, one ... therapy balls) which may look more like a children's toy, ... use a slightly deflated ball of 55 to 65 centimetres ... body's stability base - so you have to work your ...
Other Medicine News:Health News:Abortion made easy pill causes alarm in state 2(Date:3/17/2010)... Alpharma Inc. has agreed to pay $42.5 million to the federal government and certain states to settle a whistleblower lawsuit that ... ... , ... ... ...
(Date:3/17/2010)... announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company,s Genous Bio-engineered R stent. , ... ... ... ... Margo Klomp , M.D., of the Academic Medical Center (AMC) ...
(Date:3/17/2010)... SAN DIEGO , March 17 /PRNewswire/ ... company, announced that it has initiated a pivotal ... oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 ... to severe pain in individuals who require around-the-clock ... is the most widely prescribed drug in ...
Breaking Medicine Technology:Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 2Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 3Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 4Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 2Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 3Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 4Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan Third Consecutive Year 61000 1Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan Third Consecutive Year 61000 2CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 1CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 2CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 3CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 4Phoenix House Appoints Dr Deni Carise as Chief Clinical Officer Internationally Recognized Leader in Substance Abuse Treatment and Research 60996 1Phoenix House Appoints Dr Deni Carise as Chief Clinical Officer Internationally Recognized Leader in Substance Abuse Treatment and Research 60996 2Phoenix House Appoints Dr Deni Carise as Chief Clinical Officer Internationally Recognized Leader in Substance Abuse Treatment and Research 60996 3[0] Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States[0] Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM)[0] Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
... in Combination With Statins Improved All Three Key ... Consistent With TriLipix or Statin Monotherapies, CHICAGO, ... III,studies show that in patients with multiple lipid ... (atorvastatin and,simvastatin), significantly improved three key lipids -- ...
... At two years, Company,s TAXUS(R) and PROMUS(TM) Stents demonstrate positive ... ... Mass. and CHICAGO, March 31 Boston,Scientific Corporation (NYSE: ... (3:1), single blind, non-inferiority,SPIRIT II Trial comparing the safety and ...
Other Medicine Technology:Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL 2Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL 3Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 2Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 3Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 4A general purpose instrument for use around the femur and acetabulum....
Delicate side cutting wire cutter with carbide inserts....
The osteotome shafts are manufactured with stainless steel and are available both straight and curved in 1/4" and 1/2" sizes....
... a digital special purpose scintimammography camera. ... to the edge of the detector and ... as well as breast containment and stabilization ... IS2s breast scintimammography camera is a dedicated ...
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |